Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 3

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Myeloid 3

Conditions

Multiple Myeloma 155Leukemia, Lymphocytic, Chronic, B-Cell 43Lymphoma, Large B-Cell, Diffuse 26Lymphoma 25Lymphoma, Non-Hodgkin 23Lymphoma, Mantle-Cell 23Lymphoma, Follicular 23Leukemia 22Recurrence 21Neoplasms, Plasma Cell 19Myelodysplastic Syndromes 12Lymphoma, B-Cell, Marginal Zone 12Leukemia, Myeloid, Acute 12Waldenstrom Macroglobulinemia 8Smoldering Multiple Myeloma 8Hodgkin Disease 8Prostatic Neoplasms 7Lymphoma, B-Cell 6Lymphoma, T-Cell 5Lymphoma, Large-Cell, Anaplastic 5Hematologic Diseases 5Sezary Syndrome 4Mycosis Fungoides 4Lymphoma, T-Cell, Peripheral 4Leukemia, Myelomonocytic, Chronic 4Immunoblastic Lymphadenopathy 4Anemia 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Polycythemia Vera 3Lymphoma, T-Cell, Cutaneous 3

Interventions

fludarabine phosphate 18Whole-Body Irradiation 12Peripheral Blood Stem Cell Transplantation 12Mycophenolic Acid 11ruxolitinib 10Busulfan 10Tacrolimus 9Cyclophosphamide 9fludarabine 6Methotrexate 5Melphalan 5Cyclosporine 5Hydroxyurea 4Antilymphocyte Serum 4pomalidomide 3givinostat hydrochloride 3givinostat 3Stem Cell Transplantation 3Prednisone 3Lenalidomide 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3thymoglobulin 2peginterferon alfa-2a 2merphos 2Surveys and Questionnaires 2Radiotherapy 2Imatinib Mesylate 2Etoposide 2Dasatinib 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Polycythemia Vera × Lenalidomide × Clear all
NCT01375140 2025-06-08

Ruxolitinib and Lenalidomide for Patients With Myelofibrosis

M.D. Anderson Cancer Center

Phase 2 Completed
31 enrolled 8 charts
Myeloid

Polycythemia Vera, Primary Myelofibrosis

NCT01243944 2019-03-06

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

Incyte Corporation

Phase 3 Completed
222 enrolled 21 charts
Myeloid

Polycythemia Vera

NCT00227591 2014-05-21

Lenalidomide and Prednisone in Treating Patients With Myelofibrosis

National Cancer Institute (NCI)

Phase 2 Completed
48 enrolled 7 charts
Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡